Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216550 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL28636550 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL30542351 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL30542352 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL217106 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL215922 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL25485911 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL217428 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| Cyclohexane Carboxamide SCHEMBL26181 | 1.00 | — | — | |
| SCHEMBL27938035 | 1.00 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452521-A1 | TETRAHYDROINDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2017192226-A1 | TETRAHYDROINDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-11-09 | — | — | WO | claimed |
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | claimed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| EP-0486386-B1 | Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them | ADIR (FR) | 1996-07-17 | — | — | EP | claimed |
| EP-0486386-A2 | Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them | ADIR ET COMPAGNIE (FR) | 1992-05-20 | — | — | EP | claimed |
| CN-119684317-A | Macrocyclic compound and application thereof | 郑州德迈药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-113462278-B | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240084056-A1 | Polyolefin-Based Ionomers and Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4271718-A1 | POLYOLEFIN-BASED IONOMERS AND PRODUCTION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11766669-B2 | Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-4118584-A | 9-Deoxy-9-methylene-16-phenyl-PGF compounds | THE UPJOHN COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4110532-A | PROSTAGLANDINS, SMOOTH MUSCLE STIMULANTS | THE UPJOHN COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4098805-A | 9-DEOXY-9-METHYLENE-PGF-TYPE AMIDES | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766669-B2 | Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof | MLX, ZYX, TXN | CES2 4035/4885CES1 3464/4885KDM4E 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.